公开(公告)号：EP1814986B1

公开(公告)日：2011-02-16

申请号：EP05809259.4

申请日：2005-11-24

申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS VI) ,  INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)

发明人： GERTLER, Arieh ,  CALLEBAUT, Isabelle ,  DJIANE, Jean

IPC分类号： C12N15/10

CPC分类号： C07K14/5759 ,  A61K47/60

公开(公告)号：EP1814986A2

公开(公告)日：2007-08-08

申请号：EP05809259.4

申请日：2005-11-24

申请人： Yissum Research Development Company of the Hebrew University of Jerusalem ,  UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) ,  INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)

发明人： GERTLER, Arieh ,  CALLEBAUT, Isabelle ,  DJIANE, Jean

IPC分类号： C12N15/10

CPC分类号： C07K14/5759 ,  A61K47/60

摘要： The invention relates to synthetic leptin antagonists in which at least two amino acid residues of the sequence LDFI/S of the hydrophobic binding site at positions 39-42 of a leptin polypeptide sequence are substituted with different amino acid residues such that the site becomes less hydrophobic, and fragments of said leptin antagonists.

公开(公告)号：EP2560671B1

公开(公告)日：2014-09-24

申请号：EP11720887.6

申请日：2011-04-17

申请人： Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. ,  The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center

发明人： GERTLER, Arieh ,  ELINAV, Eran ,  HALPERN, Zamir

IPC分类号： A61K38/22 ,  A61P5/50 ,  A61P29/00 ,  A61P37/06 ,  A61P25/28 ,  A61P9/10

CPC分类号： C07K14/5759 ,  A01K2217/00 ,  A61K31/05 ,  A61K31/575 ,  A61K38/22 ,  A61K38/2264 ,  A61K38/28 ,  A61K45/06 ,  A61K47/60 ,  A61K49/0008 ,  A61K2300/00

公开(公告)号：EP2560671A2

公开(公告)日：2013-02-27

申请号：EP11720887.6

申请日：2011-04-17

申请人： Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. ,  The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center

发明人： GERTLER, Arieh ,  ELINAV, Eran ,  HALPERN, Zamir

IPC分类号： A61K38/16 ,  A61K38/22

CPC分类号： C07K14/5759 ,  A01K2217/00 ,  A61K31/05 ,  A61K31/575 ,  A61K38/22 ,  A61K38/2264 ,  A61K38/28 ,  A61K45/06 ,  A61K47/60 ,  A61K49/0008 ,  A61K2300/00

摘要： Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated.